Clinical trial
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
NCT03662035 is registered in ClinicalTrials.gov with Changzhou No.2 People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
- Lead sponsor
- Changzhou No.2 People's Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 15, 2018
- Completion date
- August 1, 2020
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced pancreatic cancer